1. Home
  2. NBIX vs TECH Comparison

NBIX vs TECH Comparison

Compare NBIX & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$162.00

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$72.08

Market Cap

11.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
TECH
Founded
1992
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
11.2B
IPO Year
1996
1995

Fundamental Metrics

Financial Performance
Metric
NBIX
TECH
Price
$162.00
$72.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
22
11
Target Price
$180.91
$71.82
AVG Volume (30 Days)
1.3M
3.7M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
0.62%
EPS Growth
41.95
N/A
EPS
3.30
0.81
Revenue
$161,626,000.00
$1,219,635,000.00
Revenue This Year
$24.73
$2.49
Revenue Next Year
$13.14
$6.40
P/E Ratio
$50.32
$89.00
Revenue Growth
977.51
5.23
52 Week Low
$122.14
$43.20
52 Week High
$186.12
$72.37

Technical Indicators

Market Signals
Indicator
NBIX
TECH
Relative Strength Index (RSI) 40.24 73.83
Support Level $153.96 $70.49
Resistance Level $169.57 $72.22
Average True Range (ATR) 6.37 0.32
MACD -2.08 -0.59
Stochastic Oscillator 0.64 66.12

Price Performance

Historical Comparison
NBIX
TECH

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Share on Social Networks: